The aim of this study was to determine the effects of 125I seeds on prostate carcinoma (PC3) cells. The relative biological effectiveness of 125I seeds on PC3 cells with respect to 60Co γ rays was 1.4. Both 4 Gy of 60Co γ ray and 125I seed irradiation increased the percentage of cells in G2 phase, but there was no significant difference between these 2 types of radiation. Significantly, 125I seeds induced higher apoptotic rates of PC3 cells compared with 60Co γ ray irradiation. Furthermore, Bcl-2 expression, but not caspase-3 activity, in PC3 cells was downregulated after irradiation with 125I seed or 60Co γ rays.
Yu Y., Anderson L., Li ZF, et al. Permanent prostate seed implant brachytherapy: Report of the American Association of Physicists in Medicine Task Group No. 64. Med Phys. 2005;26:2054-2076.
2.
Harrison LBApplication of brachytherapy in head and neck cancer. Semin Surg Oncol. 1997;13:177-184.
3.
Purohit RS, Shinohara K., Meng MV, Carroll PRImaging clinically localized prostate cancer. Urol Clin North Am. 2003; 30:279-293.
4.
Jemal A., Murray T., Samuels A., Ghafoor A., Ward E., Thun MJCancer statistics. CA Cancer J Clin. 2003;53:5-26.
5.
Montemaqqi P. , Dobelbower R., Crucitti F., et al. Interstitial brachytherapy for pancreatic cancer: report of seven cases treated with 125I and a review of the literature . Int J Radiat Oncol Biol Phys. 1991;21:451-457.
6.
Nath R., Anderson LL, Luxton G., Weaver KA, Wilianson JF, Meigooni ASDosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. Med Phys. 1995;22:209-234.
7.
Reniers B., Vynckier S., Verhaegen F.Theoretical analysis of microdosimetric spectra and cluster formation for Pd-103 and I-125 photon emitters. Int J Radiat Oncol Biol Phys. 2004; 49:3781-3795.
8.
Yue N., Chen Z., Nath R.Edema-induced increase in tumour cell survival for I-125 and Pd-103 prostate permanent seed implants a mathematical model. Int J Radiat Oncol Biol Phys. 2005;47:1185-1204.
9.
Nickers P., Coppens L., Jansen N., Deneufbourg JM192Ir low dose rate brachytherapy for boosting locally advanced prostate cancers after external beam radiotherapy: a phase II trial. Radiother Oncol. 2006;79:329-334.
10.
Merrick GS, Butler WM, Galbreath RW, Lief JHFive-year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer. Int J Radiat Oncol Biol Phys. 2001;51:41-48.
11.
Richard E., Grimm PD, Blasko JC, Sylvester JE, Meier RM, Cavanagh W.10-year biochemical (prostate specific antigen) control of prostate cancer with 125I brachytherapy. Int J Radiat Oncol Biol Phys. 2001;51:31-40.
12.
Rivard MJ, Butler WM, Devlin PM, et al. American Brachytherapy Society recommends no change for prostate permanent implant dose prescriptions using iodine-125 or palladium-103. Brachytherapy. 2007;6:34-37.
13.
Armpilia CI , Dale RG, Coles IP, et al. The determination of radiobiologically optimized half-lives for radio nuclides used in permanent brachytherapy in plants. Int J Radiat Oncol Biol Phys. 2003 ;55:378-385.
14.
Aird G., Folkard M., Mayes CR, Bownes PJ, Lawson JM, Joiner MCA purpose built iodine-125 plaque for low dose rate low energy irradiation of cell lines in vitro. Br J Radiol. 2001;74:56-61.
15.
Ling CC, Li WX, Anderson LLThe relative biological effectiveness of I-125 and Pd-103. Int J Radiat Biol Phys. 1995;32:373-378.
16.
Sambrook J., Russell D.Molecular Cloning: A Laboratory Manual. 3rd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2000:1235-1262.
17.
King CR, Dipetrillo TA, Wazer DEOptimal radiotherapy for prostate cancer: predictions for conventional external beam, IMRT, and brachytherapy from radiobiologic models. Int J Radiat Oncol Biol Phys. 2001;46:165-172.
18.
Merrick GS, Butler WM, Galbreath RW, Lief JH, Adamovich E.Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland. Int J Radiat Oncol Biol Phys. 2002;52:664-673.
19.
Nickers P., Thissen B., Jansen N., Deneufbourg JM192Ir or 125I prostate brachytherapy as a boost to external beam radiotherapy in locally advanced prostatic cancer: a dosimetric point of view. Radiat Res. 2006;78:47-52.
20.
Wang JZ, Mayr NA, Nag S., et al. Effect of edema relative biological effectiveness and dose heterogeneity on prostate brachytherapy. Med Phys. 2006;33:1025-1032.
21.
Lehnert S., Reniers Brigitte, Verhaegen F.Relative biologic effectiveness in terms of tumor response of 125I implants compared with 60Co gamma rays. Int J Radiat Oncol Biol Phys . 2005;63:224-229.
22.
Ichard T.Relative biological effectiveness enhancement of a 125I brachytherapy seed with characteristic X rays from its constitutive materials. Med Phys. 2002;29:1397-1402.
23.
Mitchell R. , Joiner C.Effect of subsequent acute-dose irradiation on cell survival in vitro following low dose-rate exposures. Int J Radiat Biol. 2002;78:981-990.
24.
Scott SL, Gumerlock PH, Beckett L., Goldberq Z.Survival and cell cycle kinetics of human prostate cancer cell lines after single and multifraction exposures to ionizing radiation. Int J Radiat Oncol Biol Phys. 2004;59:219-227.
25.
Enns L., Bogen KT, Wizniak J., Murtha AD, Weinfeld M.Low-dose radiation hypersensitivity is associated with p53-dependent apoptosis . Mol Cancer Res. 2004;2:557-566.
26.
Joiner MC, Marples B., Lambin P., Short SC, Turesson I.Low-dose hypersensitivity: current status and possible mechanisms. Int J Radiat Oncol Biol Phys. 2001;49:379-389.
27.
Nakamura H. , Yasui Y., Saito N., Tachibana A., Komatsu K., Ishizaki K.DNA repair defect in AT cells and their hypersensitivity to low-dose-rate radiation. Radiat Res. 2006 ;165: 277-282.
28.
Collis SJ, Schwaninger JM, Ntambi AJ, et al. Evasion of early cellular response mechanisms following low level radiation-induced DNA damage. J Biol Chem. 2004,279: 49624-49632.
29.
Carlsson J. , Håkansson E., Eriksson V., et al. Early effect of low dose-rate radiation on cultured tumor cells. Cancer Biother Radiopharm. 2003;18:663-670.
30.
Krueqer SA, Joiner MC, Weinfeld M., Piasentin E., Marples B.Role of apoptosis in low-dose hyper-radiosensitivity. Radiat Res. 2007;167:260-267.
31.
Michael, Wang L., Handly JRIonizing radiation-induced mitogen-activated protein (MAP) kinase activation in DU-145 prostate carcinoma cells: MAP kinase inhibition enhances radiation-induced cell killing and G2/M-phase arrest. Radiat Res. 2000;153:371-383.
32.
Tang DG, Li L., Chopra DP, Porter ATExtended survivability of prostate cancer cells in the absence of trophic factors: increased proliferation evasion of apoptosis,and the role of apoptosis proteins. Cancer Res. 1998;58:3466-3479.
33.
Lowe SL, Rubinchik S., Honda T., Mcdonnell TJ, Dong JY, Norris JSProstate-specific expression of Bax delivered by an adenoviral vector induces apoptosis in LNCaP prostate cancer cells. Gene Ther. 2001;818:1363-1371.
34.
Shi CJ, Zeng HH, Li HW, Yang FG, Wu XQ, Yu LZInduction of apoptosis in prostate cancer cell line PC-3 by BBSKE, a novel organoselenium compound, and its effect in vivo [in Chinese]. Zhonghua Yi Xue Za Zhi. 2003;83:1984-1988.
35.
Szostak MJ, Kaur P., Amin P., Jacobs SC, Kyprianou N.Apoptosis and bcl-2 expression in prostate cancer: significance in clinical outcome after brachytheray. J Urol. 2001;165:2126-2130.
36.
Bondar VM, McConkey DJAnoikis is regulated by BCL-2-independent pathways in human prostate carcinoma cells. Prostate. 2002;51:42-49.
37.
Keledjian K. , Kyprianou N.Anoikis induction by quinazoline based alpha 1-adrenoceptor antagonists in prostate cancer cells: antagonistic effect of bcl-2. J Urol. 2003;169: 1150-1156.
38.
Mirzaie-Joniani H., Eriksson D., Sheikholvaezin A., et al. Apoptosis induced by low-dose-rate radiation. Cancer. 2002;94: 1210-1214.
39.
Kroger LA, Denardo GL, Gumerlock PH, et al. Apoptosis-related gene and protein expression in human lymphoma xenografts (Raji) after low dose rate radiation using 67Cu-217-BAT-Lym-l radioimmunotherapy . Cancer Biother Radiopharm. 2001;16:213-225.
40.
Yacoub A., Mckinstry R., Hinman D., Chung T., Dent P., Hagan MPEpidermal growth factor and ionizing radiation up-regulate the DNA repair gens XRCC1 and ERCC1 in DU145 and LNCaP prostate carcinoma through MAPK signaling . Radiat Res. 2003;159:439-452.
41.
Bromfield GP , Meng A., Warde P., Bristow RGCell death in irradiated prostate epithelial cells: role of apoptotic and clonogenic cell kill. Prostatic Dis. 2003;61:73-85.
